Published in Healthcare Mergers, Acquisitions and Ventures Week, February 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at AstraZeneca.
Report 1: New phase IIb data from the Disperse2 Study presented at the American Heart Association's Scientific Sessions, assessed the safety and tolerability of the AstraZeneca investigational drug AZD6140 plus aspirin compared with clopidogrel plus aspirin as antiplatelet therapy in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
The primary end point of the study was the incidence of total (major plus minor) bleeding events seen in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week